Nigeria is not mainly a hard market to register in. It is a market being closed to imports molecule by molecule, on two published lists, on a published clock — and for a product on either of them NAFDAC states in its own guidelines that it will not entertain the application at all. Not the renewal either.
NAFDAC publishes two lists that between them decide whether Nigeria is a market for your product at all. The Ceiling List — 36 active substances that, in NAFDAC's words, "can only be registered as locally manufactured Pharmaceuticals". And the 5+5 list — 29 products under a policy requiring foreign manufacturers to migrate to local or contract manufacture, with de-registration at the end of it.
Type an active substance below. This runs in your browser against the two published lists and sends nothing anywhere.
Both lists as NAFDAC publishes them. A match is a reason to stop and rethink the commercial structure, not a reason to file harder.
Sixty-five entries across the two lists, including a number that appear on both.
Published 15 November 2021 and maintained as a note to industry. NAFDAC's registration guideline DRR-GDL-005-03 states it will not entertain new applications for imported products on it.
Policy instituted March 2019, list published 1 May 2019. NAFDAC's renewal guideline DRR-GDL-025-04 states it will not entertain renewal applications for imported products on it.
For a listed molecule you can neither enter nor stay. A UK company exporting imported amoxicillin, metformin, omeprazole or ciprofloxacin to Nigeria is not facing a harder renewal — it is facing a renewal NAFDAC has said in writing it will not process. The regulatory question becomes moot, and the real question is whether you want a Nigerian contract-manufacturing partner.
A constitutional oddity worth knowing. These are the two most commercially consequential instruments in Nigerian medicines regulation for a UK exporter, and neither is a statute or a gazetted regulation. The 5+5 Policy is described by NAFDAC itself as "a regulatory directive"; the Ceiling List is a note to industry. They work through the Agency's discretion to decline to entertain applications. That does not make them any less binding in practice — but it does mean they can change without a gazette, in either direction.
The 5+5 Policy gives a foreign manufacturer five years, then five more, on the condition that it migrates to Nigerian production — by partnership, contract manufacture or its own plant. NAFDAC publishes the milestones.
NAFDAC, "Five Plus Five-Year Validity (Migration to Local Production)" and "Commencement of Five Plus Five Year Validity" #03191R. The policy does carve out that not all products can be made locally, allowing continued importation where domestic capacity is genuinely insufficient — but that is a discretionary carve-out, not a right, and it is not a plan.
NAFDAC publishes what it thinks this has achieved: 191 facility-layout applications received and 185 approved, of which 108 from wholly new manufacturers; 53 plants finished; over seventy per cent of 5+5 products now made in Nigeria; imports of 5+5 and Ceiling products down from about seventy per cent of supply to about fifty. Whatever you make of the numbers, they are the numbers the policy is being steered by.
On the devices side of this site we published two conflicting Nigerian timelines because the regulator publishes two. On medicines there are three, and the story is sharper: NAFDAC did not let its timeline slip. It formally doubled it, in a signed directive, and said why.
Days, in NAFDAC's SERVICOM charter — a document with no date on it, and plainly stale.
Working days, the previous published registration timeline for drug products.
Working days, by directive NAFDAC-RDRT-038-00 effective 1 May 2025 — new, renewal and variation alike.
The directive gives its own reason: "to align registration timelines with operational realities." Two hundred and forty working days is roughly eleven to twelve months of clock before anything stops it.
Guideline DRR-GDL-005-03 §10.11: "the clock stops once compliances are issued." §10.9: failure to answer a query within 90 working days closes the application automatically. So the Agency's clock pauses whenever it asks you something, and yours runs the whole time. Two hundred and forty working days is a floor, not an estimate.
Renewals run on their own shorter clock — 90 working days, with the application due not later than six months before expiry and a 45-working-day query deadline. Registration is valid five years under regulation 3(4) of the 2021 Registration Regulations.
The MHRA received full WHO Listed Authority designation on 7 August 2025. NAFDAC's reliance directive naming WHO Listed Authorities took effect on 11 October 2025. The sequence is favourable: NAFDAC wrote that directive in a world where the MHRA was already a WLA.
But NAFDAC published two reliance documents sixteen days apart, and they do not say the same thing.
Practical advice, and we would give it to a client in exactly these words: lead with the directive, not the guideline. An MHRA-approved product qualifies under RDRR-005-04 §2.1.1 and §3.3.2 or §3.3.5 — but the operative registration guideline still frames eligibility by a list frozen in 2015 that does not contain you, so expect to have to argue it, and have the citation ready before the first query arrives. The same pattern in five other markets →
What the route is worth. Reliance guideline §8.3: NAFDAC makes its registration decision "within 60 working days (approximately 90 calendar days)". The WHO collaborative registration procedure carries the same 60 working days. Against a baseline of 240, this is the single largest lever on the page — and it costs nothing but the right paperwork and the right citation.
NAFDAC categorises every dossier by risk, and the category decides how hard the review is. The line that separates low from medium is not about your product at all. It is about your disclosure policy.
Products approved by an SRA or a WHO maturity-level-3 agency "for which the unredacted assessment report can be shared or accessed"
Products from an SRA "for which unredacted assessment report(s) cannot be shared with NAFDAC"
New molecules, new dosage forms, products from a new manufacturer in a non-SRA region — and everything containing glycerin, propylene glycol, maltitol, sorbitol or hydrogenated starch hydrolysate
Guideline DRR-GDL-033-01, effective 7 December 2024. The excipient rule in the high-risk row is the diethylene-glycol contamination class and it applies regardless of origin — a perfectly ordinary paediatric syrup lands there. Note also the escalation clause: a company that has paid an administrative fine over a quality issue moves up a category. Whether your company will release the complete unredacted MHRA assessment report to a third-country regulator is usually a legal and commercial call made a long way from regulatory affairs. In Nigeria it is the call that sets your pathway.
This is the same finding as on the devices page, and it is worth stating precisely because it is unusual. We read the Act and the gazetted regulation, and the conditions a UK exporter actually has to satisfy are in neither.
Everything in the left column hangs off that open-ended phrase in regulation 3(1). We searched the gazette text for "agent", "attorney", "trademark" and "Corporate Affairs" and found none of them — with the caveat that the accessible copy is a scanned gazette with imperfect optical recognition, so we call this confirmed absent from a legible but imperfect text rather than from a clean one. Practical consequence: a transfer of agency is possible with NAFDAC's approval and there is a fee line for it, but no procedure for obtaining that approval is published anywhere. Settle who holds the registration in the contract, because the exit is undocumented.
Three documents must each be "authenticated by the Nigerian Embassy or High Commission in the country of origin": the Certificate of Pharmaceutical Product, the current GMP certificate and the foreign manufacturing licence. Where there is no Nigerian mission, any Commonwealth or ECOWAS country may authenticate. This is consular legalisation; the apostille does not appear anywhere in these guidelines.
Two details that catch people. The CPP must come from the authority in the country of manufacture, not the country of your marketing authorisation — a UK holder manufacturing in Ireland or India needs the Irish or Indian certificate, legalised at the Nigerian mission there. And the notarised declaration is signed by the Nigerian applicant's managing director and says, in terms, "We agree to be held criminally liable for any false declaration made herein and forged documents submitted." That is a real ask of a local partner, and it is worth raising with them early rather than at signature.
NAFDAC's only published tariff took effect on 31 January 2020 and is still the only one linked from its own tariff page. Amounts marked in dollars are payable in the naira equivalent.
| Item | Local | Imported |
|---|---|---|
| Registration — prescription medicine, type POM 1 | ₦80,000 | US$1,280 |
| Registration — prescription medicine, type POM 2 | ₦80,000 | US$1,200 |
| Registration — over-the-counter medicine | ₦80,000 | US$967 |
| Registration — orphan drug | ₦80,000 | US$967 |
| Renewal of registration | 80% of the new registration fee | |
| Additional manufacturing source or site | the same as a new registration | |
| GMP inspection of a foreign site | per line, ₦50,000–170,000 | US$10,989.01 per site |
| Desk review, site already inspected | — | US$5,000 |
| Fast-track processing | double the cost of the activity | |
Laboratory analysis and the import permit are not separate lines for an imported product — NAFDAC's own note says they are embedded in the registration fee. Foreign facility inspections are valid three years. We read all fourteen pages looking for a per-inspector, travel or per-diem component and there is none; the foreign inspection fee is a single flat figure. Anyone quoting you a travel line for it is not quoting NAFDAC.
POM 1 is defined in the tariff's own notes as "Medicines that can be manufactured in Nigeria". POM 2 is "Medicines with no existing manufacturing facility in Nigeria". A foreign applicant pays more to register a medicine Nigeria could make itself. The eighty-dollar differential is trivial; the taxonomy is not. It is the same "can Nigeria make this?" test that drives the Ceiling List, showing up in the fee schedule.
On economics: a $10,989 inspection against a $1,200 registration means first entry only works if a portfolio sits behind one inspection, or if the site already qualifies for the $5,000 desk review — and that desk review is gated on the site having been inspected already. It is a second-product economy, not a first-entry waiver. The reliance route offers the other way round it: NAFDAC may rely on inspection and audit reports not more than three years old, which is how an MHRA GMP inspection can stand in for a NAFDAC visit.
We looked for a price-control instrument and there is none. The Price Control Act's schedule of controlled commodities lists bicycles, flour, matches, milk, motorcycles, motor vehicles, petroleum products, salt and sugar. Pharmaceuticals are not on it. NAFDAC publishes no pricing rule, no reference basket and no mark-up regulation.
So the constraint on a Nigerian business case is not a ceiling price. It is the currency. Since October 2023 the Central Bank has removed the restriction on foreign exchange for the previously ineligible commodities — medicines were never among them — and runs a unified willing-buyer, willing-seller market under a managed float. There is no prohibition on paying a foreign supplier. The constraint is availability and rate, not permission.
What actually happened to the multinationals. Nigeria did not ban GSK or Sanofi and does not cap their prices; both moved from a direct commercial presence to third-party distribution over 2023–24. The consistent explanation in the trade press is currency: free pricing plus a floating, historically illiquid naira plus dollar-denominated regulator fees plus a ten-year localisation escalator. We have no company filing for this and report it as reputable trade press rather than as fact — but the structure it describes is visible in every primary document on this page.
Section 2 of the National Drug Formulary and Essential Drugs List Act 1989 says: "No person shall import into, advertise, display for sale, sell or manufacture in Nigeria any drug which is not contained in the List." On its face that is an absolute import prohibition for anything off the essential medicines list. NAFDAC's registration guidelines, the gazetted 2021 regulations and the risk-categorisation guideline make no reference to it, and NAFDAC plainly registers products that are not on the list. It reads as dormant. It is also unrepealed — and you should learn that from us rather than from a letter.
NAFDAC was admitted as the 24th member at the ICH Assembly of 18–19 November 2025, with a commitment to full and consistent implementation of ICH guidelines
NAFDAC and the Pharmacists Council of Nigeria became pre-applicants, with a rapporteur designated 15 August 2025. Not a member, and not yet a full applicant
First attained 2022 as Africa's first non-producing national authority; reaffirmed effective 30 June 2025 after re-benchmarking
A full study report becomes a prerequisite for new registration from January 2026, and bioequivalence is being pushed into renewals as well
The bioequivalence row is the one to plan for: a product that has sat on the Nigerian market for fifteen years on a bibliographic file can now meet a bioequivalence wall at renewal. NAFDAC's scientific guideline on bioequivalence, effective 5 May 2025, is aligned to ICH M13 and does not require the study to be run in Nigeria; its separate contract-research-organisation regime governs studies conducted there. We read that as foreign data being acceptable, but NAFDAC has not said so in terms, so we mark it an inference from two documents rather than a quoted rule.
NAFDAC's tariff page links only the edition effective 31 January 2020. Given what the naira has done since, the naira lines are almost certainly stale in practice — but no revised tariff is published. Anyone quoting current naira NAFDAC fees is not quoting NAFDAC.
The Presidential initiative gives a title and a date of 11 October 2024; the trade press reported a signing on 28 June 2024; the Ministry of Information confirms an implementation framework cleared for gazetting. No number, no gazetted text. We do not publish one.
Regulation 2(4) requires the Agency's approval and the tariff has a fee line for it. No procedural document exists that we could find.
The National Health Insurance Authority Act 2022 is in force, but we found no NHIA medicines formulary and no published route by which a product becomes reimbursable.
The Bureau of Public Procurement's site failed certificate verification, so we did not read the preference sections of the Public Procurement Act 2007 and do not quote them.
Change of agencyship, pharmacovigilance annual fees, and one unlabelled line — the tariff's table columns do not survive text extraction cleanly. We would rather leave them blank than print a misaligned number.
Every NAFDAC document cited on this page was read in full from NAFDAC's own server. The gazetted 2021 regulations were read from a scanned copy with imperfect optical recognition, and that limitation is stated where it affects a conclusion.
The device page for Nigeria turns on a promise: the 2024 UK–Nigeria partnership says Nigeria will recognise the UKCA mark, in a document that expressly creates no binding obligations and which nothing has implemented. On medicines that same agreement does less. Pharmaceuticals appear only under "Encourage collaboration", and the one substantive bullet frames good-manufacturing-practice cooperation as serving local drug manufacture rather than imports. The route that does work for medicines is the reliance directive, and it has nothing to do with the trade agreement.
The medical devices page for Nigeria → · What an MHRA approval is worth in all six markets →
Send us the molecule and we will tell you within a day whether Nigeria is a registration project, a contract-manufacturing conversation or neither — before you commission anything. It is the cheapest answer we give, and sometimes it is the one that saves the year.
Or reach us directly — mail@bcabusiness.co.uk · +44 7342 901002 · WhatsApp
Re-checked quarterly, and immediately on any revision of the Ceiling List or the 5+5 list — either of which can add or remove a product from this market without a gazette. The molecule check above is a convenience, not a legal opinion: confirm against NAFDAC's published lists before acting, and talk to us if your product is close to a listed one.